Gender difference in the interaction of smoking and monoamine oxidase B intron 13 genotype in Parkinson's disease.
We tested for gender-specific interactions between smoking and genetic polymorphisms of monoamine oxidase B (MAO-B) intron 13 (G or A allele), monoamine oxidase A (MAO-A) EcoRV (Yor N allele), and dopamine D2 recepor (DRD2) Taq1B (B1 or B2 allele) in a case-control study of 186 incident idiopathic Parkinson's disease (PD) cases and 296 age- and gender-matched controls. The odds ratios (ORs) for PD risk for ever smokers versus never smokers were 0.27 (95% CI: 0.13-0.58) for men of genotype G, and 1.26 (0.60-2.63) for men of genotype A (interaction chi2 = 8.14, P = 0.004). In contrast, for women, the OR for ever smokers versus never smokers were 0.62 (95% CI: 0.25-1.34) and 0.64 (95% CI: 0.18-2.21) for women of genotype GG/GA and AA, respectively (interaction chi2 = 0.001, P = 0.975). No interactions were detected between smoking and either MAO-A EcoRV or DRD2 Taq1B genotypes. These results suggest that a strong gender difference exists with respect to the modifying effect of MAO-B genotype on the smoking association with PD.
Kelada
Samir N
SN
Department of Environmental Health, University of Washington, Seattle 98195, USA. skelada@u.washington.edu
Costa-Mallen
Paola
P
Costa
Lucio G
LG
Smith-Weller
Terry
T
Franklin
Gary M
GM
Swanson
Phillip D
PD
Longstreth
W T
WT
Checkoway
Harvey
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003625:Data Collection; D015252:Deoxyribonucleases, Type II Site-Specific / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D007438:Introns / Q000235:genetics / Q000502:physiology; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000235:genetics* / Q000378:metabolism; D010300:Parkinson Disease / Q000201:enzymology* / Q000235:genetics*; D011153:Population; D012727:Sex Characteristics; D012907:Smoking / Q000235:genetics / Q000378:metabolism*
D008995:Monoamine Oxidase; D015252:Deoxyribonucleases, Type II Site-Specific; C027440:GATATC-specific type II deoxyribonucleases